Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease
Public ClinicalTrials.gov record NCT00842088. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Blinded, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 in Subjects With Sickle Cell Disease
Study identification
- NCT ID
- NCT00842088
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- HemaQuest Pharmaceuticals Inc.
- Industry
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- HQK-1001 Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2009
- Primary completion
- Jun 30, 2010
- Completion
- Not listed
- Last update posted
- Jul 31, 2011
Started 2009
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Trialogic Research | Madison | Alabama | 35758 | — |
| Children's Hospital and Research Center at Oakland | Oakland | California | 94609 | — |
| Century Clinical Research, Inc. | Daytona Beach | Florida | 32117 | — |
| Medical College of Georgia | Augusta | Georgia | 30912 | — |
| University of Illinois at Chicago | Chicago | Illinois | 60612 | — |
| Johns Hopkins School of Medicine | Baltimore | Maryland | 21205 | — |
| UNC Comprehensive Sickle Cell Program | Chapel Hill | North Carolina | 27599 | — |
| Texas Children's Cancer Center and Hematology Service | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00842088, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 31, 2011 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00842088 live on ClinicalTrials.gov.